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6XPPDU\RIWKHDUWLFOH¶VPDLQSRLQWV 
Despite limitations, human challenge trials could accelerate a COVID-19 vaccine by providing 
signals of vaccine efficacy in as little as two months or by identifying surrogates of protection. Trial 
preparations would take many months and thus, should be started immediately. 
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Abstract 
Human challenge trials (HCTs) have been proposed as a means to accelerate SARS-CoV-2 
vaccine development. In this paper, we discuss the potential roles for such studies in the current 
COVID-19 pandemic. We present three potential use cases of HCTs: evaluating efficacy, 
converging on correlates of protection, and improving understanding of pathogenesis and the 
human immune response. We go on to outline the limitations of HCTs and conclude that, while 
currently limited in their application, there are scenarios in which HCTs would be vastly beneficial 
and, therefore, the option of conducting HCTs to accelerate COVID-19 vaccine development 
should be preserved. Thus, we recommend an immediate, coordinated effort by all stakeholders 
to (1) establish guidelines for the use of HCTs for COVID-19; (2) take the first steps toward HCTs, 
including preparing challenge virus and making preliminary logistical arrangements; and (3) 
commit to periodically re-evaluating the utility of HCTs amid the evolving pandemic. 
 
Keywords: Vaccine evaluation; COVID-19; Pandemic; Controlled Human Infection; Human 
Challenge Trial  
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Introduction 
As of May 17, 2020, SARS-CoV-2 has led to almost 4.5 million confirmed infections worldwide 
and over 300,000 deaths.1 9DFFLQHV DUH VHHQ DV KXPDQLW\¶V EHVW ZHDSRQ DJDLQVW WKH YLUXV
Organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI) have 
advocated measures to shorten vaccine development times, such as conducting phase 1 clinical 
trials in parallel with animal testing.2 Still, even with these urgent measures, in February the World 
Health Organization (WHO) optimistically projected 12±18 months until a vaccine could be 
available, with potential further manufacturing and regulatory delays,3 although several initiatives 
have announced more aggressive targets.4 
 
Human challenge trials (HCTs) present an opportunity to hasten vaccine development. In HCTs, 
healthy volunteers are administered a vaccine candidate, and then an infectious dose of 
pathogen. The outcomes of this infection are tracked, providing a unique opportunity to assess a 
YDFFLQHFDQGLGDWH¶VSHUIRUPDQFH 
 
Historically, HCTs have provided crucial information about human-pathogen interactions.5 HCTs 
have demonstrated the efficacy of cholera vaccines prior to large field trials, while malaria 
challenges gave early indications regarding the possible efficacy of RTS,S/AS01, the leading 
malaria vaccine candidate.6, 7 
 
Eyal et al. suggested that HCTs could speed up COVID-19 vaccine development by several 
months.8 Even a modest acceleration, they argued, could theoretically avert many deaths. This 
and similar proposals have sparked substantial dialogue around HCTs.9 
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In this paper, we discuss three potential use cases for HCTs in the current COVID-19 pandemic, 
the preparatory steps needed to make them possible, and how to proceed while deciding whether 
to conduct HCTs for COVID-19 vaccine development. 
Use cases for HCTs in COVID-19 vaccine development 
In the context of the COVID-19 pandemic, HCTs could help evaluate vaccine efficacy, identify 
correlates of protection, and understand pathogenesis and the immune response. 
Evaluating efficacy 
HCTs could be used alongside an expanded safety trial to replace phase 3 trials, or in parallel 
with phase 3 trials to give an early indicator of efficacy.  
 
Eyal et al. suggested that HCTs could be used to test for efficacy and, in combination with a large-
scale short-term expanded phase 2 safety study, replace comparably lengthy phase 3 trials.8 
Phase 3 trials often take years and usually at least many months.10 However, governments, 
vaccine manufacturers, and other stakeholders are currently moving to develop a vaccine at 
unprecedented speed.11 The WHO Solidarity Trial expects to shorten the time to generate efficacy 
data from their trial to three to six months, if the trial is conducted in regions with high COVID-19 
incidence or in high-risk populations such as healthcare workers.12 Other stakeholders will likely 
conduct phase 3 trials with similar populations.13 However, it might become harder to identify 
suitable populations at high risk of infection if COVID-19 incidence falls or fluctuates unpredictably 
due to social restrictions. Two studies in China examining the effects of the potential drug 
treatment remdesivir were forced to shut down when they were unable to recruit enough patients 
due to low disease incidence.14 
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With the necessary preparations and approvals in place, an HCT could take as little as two months 
to conduct and would require far fewer participants than a phase 3 trial due to viral exposure being 
guaranteed by the challenge. Therefore, HCTs could accelerate the licensure of a vaccine. 
 
Our two month estimate includes: 
- At least two weeks in isolation to screen volunteers for prior infection and other 
exclusionary health factors, 
- At least two weeks after vaccination to allow for an immune response, and possibly longer 
if administering multiple consecutive doses, 
- At least four weeks after viral challenge to observe and resolve infection endpoints and 
document the end of viral shedding. 
 
There is precedent for licensing on the basis of HCT efficacy data: such data, in combination with 
conventional trials measuring safety and immunogenicity, provided the basis for licensing the first 
FDA-approved cholera vaccine.15 However, an HCT replacing a phase 3 trial would at least have 
to be accompanied by an expanded safety trial, which would take additional time and might sti ll 
not suffice for vaccine licensure. At a minimum, post-licensure trials would be necessary to 
FRQWLQXRXVO\HYDOXDWHWKHYDFFLQH¶VHIILFDF\DQGVDIHW\ 
 
Instead of  replacing phase 3 trials, HCTs could be used in conjunction with them to provide an 
early glimpse of efficacy in advance of phase 3 results. This could allow manufacturers to 
reallocate time, funds and other resources from less to more promising candidates.16 Phase 3 
trials would still be useful for demonstrating efficacy across the population under real-world 
conditions and the frequency of any rare adverse effects of vaccination. Challenge trials may also 
enable head-to-head comparison of different vaccine candidates. 
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Converging on correlates of protection 
Correlates of protection (CoPs) are biomarkers that correlate with protection against specific 
infection outcomes. HCTs could be used to identify or verify CoPs against disease endpoints. If 
in phase 3 trials CoPs are used as surrogate endpoints instead of clinical endpoints, this could 
expedite licensure.17 Vaccines that have been approved based on CoPs include vaccines against 
hepatitis B, H5N1 influenza, and Japanese encephalitis.18, 19, 20 
 
CoPs are typically identified in animal challenge models, observational studies, or early clinical 
phases. Some vaccine manufacturers have signaled their intention to look for secondary 
outcomes that might be important CoPs.21 However, finding CoPs is a difficult task. Some viruses, 
such as rotavirus, have no known CoPs despite years of searching.22 HCTs could help establish 
CoPs for vaccine candidates if other methods fail, since the controlled clinical setting of an HCT 
provides greater opportunity to reveal links between secondary endpoints and protection. If an 
HCT established links that were causal, secondary endpoints could be used to accelerate the 
progress of many different candidate vaccines. Notably, CoPs could only accelerate the 
generation of efficacy data and not safety data. 
Improving understanding of pathogenesis and the human immune response 
Studies employing human challenge models (HCMs) could help us understand the natural history 
of COVID-19, including early stages of pathogenesis and the human immune response. HCMs 
have elucidated features of infectious diseases that could not have been studied otherwise, such 
as the evolutionary dynamics of influenza populations within a host and the dynamics of the 
immune response to common cold coronavirus 229E.23, 24 
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A COVID-19 HCM would allow close observation of the participants prior to and from the point of 
vaccination and infection, in the absence of potentially confounding coinfection. This could help 
resolve the physiological basis for variation in disease severity, the disease ¶VSURJUHVVLRQIURP
infection, or the immune response upon re-infection.25 They could thereby provide insights that 
would form a bedrock for medical countermeasure development efforts more broadly. 
 
HCTs may also have value in detecting vaccine-enhanced disease. For example, animal models 
showed increased lung pathology after vaccination with whole SARS-CoV spike protein.26 
Notably, the evidence for vaccine-enhanced disease in SARS-CoV is limited to in vitro and animal 
models, with vaccination appearing protective overall. In humans, the clinical evidence for 
vaccine-enhanced disease in SARS-CoV is scant, and the evidence for SARS-CoV-2 even more 
VR$V(\DOHWDOSURSRVH+&7VFRXOGEHGHVLJQHGWRPLQLPL]HSDUWLFLSDQWV¶H[SRVXUHWRYDFFLQH-
enhanced disease, with challenges occurring sequentially over small groups with incrementally 
increasing numbers of participants.8 
 
However, in contrast to a conventional clinical trial, an HCT may be unable to detect adverse 
events that are rare or have delayed onset. For example, time-lagged enhanced disease 
responses occurred in consecutive infections with different dengue serotypes.27 This may simply 
be from delayed exposure, but it is also possible that these effects only appear if sufficient time 
has passed between vaccination and infection. 
Limitations of HCTs 
All these approaches are limited by the extent to which data gathered from HCTs can be 
generalized to the field. Historically, some human challenge models have produced results that 
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are generally predictive of performance in the field,28 while others have not.29 The generalizability 
of HCT results depends on several factors.  
 
First, the timing of viral challenge relative to vaccination is the same for all patients in an HCT but 
highly variable in real-world use. This may prove problematic if the effects of the vaccination 
depend on the time between vaccination and infection. 
 
Second, the method of administration can affect the nature of infection and the immune response. 
For example, in influenza challenge studies, inhalation of aerosolized virus is thought to cause 
more severe, lower respiratory infection compared to intranasal instillation.30 For generalizability, 
the mode of administration should mirror routes of community-acquired infection, while balancing 
tKHPRGHO¶VUHOHYDQFHWRLQWHQGHGFOLQLFDOHQGSRLQWVDQGWKHULVNLWSRVHVWRSDUWLFLSDQWV 
 
Third, it is unclear whether field-relevant clinical endpoints are ethically feasible to test in an HCT. 
From the perspective of participant risk, it is desirable to choose the minimum infectious dose of 
challenge virus required to induce mild disease in most participants, possibly using an attenuated 
challenge virus strain to achieve this result. However, it is possible that vaccine candidates will 
more effectively abrogate severe disease than mild illness, as has been seen with influenza 
vaccine candidates.30 If such candidates were tested in HCTs with mild disease as its primary 
endpoint, their efficacy against severe disease may go undetected, along with associated CoPs. 
Additionally, if attenuated or otherwise engineered virus strains were used, they might generally 
offer less applicable results. If using wild-type virus strains or using severe disease as an HCT 
endpoint, the availability of effective therapeutic options would become an even more important 
consideration for participant safety.  
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Fourth, it may be difficult to generalize from results in pre-screened healthy young people to the 
broader global population, since responses to infection and vaccination can depend on age, 
immune status, comorbidities, infection history, genotype, and other factors.31, 32 That said, 
traditional phase 3 studies are not perfect in this regard either, as they often exclude subsets of 
the population such as children and pregnant women.33 
Preparatory steps needed for an HCT 
+&7V¶SUDFWLFDOXWLOLW\GHSHQGVFULWLFDOO\RQKRZTXLFNO\WKH\FRXOGEHSUHSDUHGDQGFRQGXFWHG
Some initial preparatory steps include: 
- Convening experts and stakeholders to develop HCT protocols, 
- Coordinating with vaccine manufacturers to design multi-arm trials, 
- Gaining approval from institutional review boards and regulatory bodies, 
- Establishing partnerships with clinical researchers and institutional sponsors, 
- Securing access to ventilators, therapeutics, and other equipment to provide the highest 
standard of care to participants in case of severe disease. 
 
For the sake of speed, these steps could be partially parallelized. Beyond these, the three main 
time-consuming steps²apart from vaccine production and initial clinical trials²are manufacturing 
challenge virus, conducting dose-finding studies, and potentially preparing clinical biocontainment 
units. 
Manufacturing challenge virus 
Before HCTs are possible, a challenge virus must be produced under good manufacturing 
practice (GMP), which only a handful of manufacturers in the US and UK are equipped to do. The 
first manufacturing steps²contracting a production facility, securing raw materials and 
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establishing a standardized protocol for production of high-quality material free of adventitious 
agents²typically take one to two months when there are no supply chain problems. From there, 
virus stocks must be produced and stored, which would take at least several weeks. After 
production, the facility needs to conduct release testing, which usually takes at least three to four 
months. (B. L. Innis, personal communication, May 9, 2020) Finally, the virus must be FDA-
approved prior to dose-finding studies. 
 
This timeline could be shortened if GMP-grade virus was already in production for other uses, 
such as for a live attenuated vaccine. Otherwise, starting production for HCTs could hasten 
other manufacturing timelines later on. 
Dose-finding studies 
Before HCTs can be performed, the infectious dose to be administered in challenges must be 
determined, typically via an escalation study. In escalation studies very few participants are 
initially administered a very low dose of virus. This initial dose could be inferred from animal 
challenges and human challenges with other viruses.34 Participants would be followed for several 
weeks in a biocontainment unit to assess the presence and severity of any resultant infections. 
This process would be repeated until some proportion of participants have reached the desired 
clinical endpoint. This means dose-finding studies carry appreciable risks for volunteers that must 
be weighed carefully. Experts estimated that a dose-finding study for a COVID-19 challenge 
model would take two to six months. (personal communications - currently seeking permission to 
cite them by name). 
 
It is worth noting that regulatory requirements for infectious dose-finding studies vary.35 In the US, 
any dose-finding studies require an Investigational New Drug application to proceed. Meanwhile, 
in at least some European countries, challenge virus is considered a Non-Investigational 
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Medicinal Product, and dose-finding studies may require fewer regulatory approvals than in the 
US.  
Preparing clinical biocontainment units 
Depending on the biosafety level required for COVID-19 HCTs, it might currently be impossible 
to conduct an HCT with sufficient participants in the same place at the same time. For example, 
isolation units used for influenza challenges typically have fewer than 40 beds (B. L. Innis, 
personal communication, May 4, 2020). Therefore, if more participants are required, HCTs may 
need to use multiple biocontainment units simultaneously with great logistical effort, or be 
performed sequentially in smaller cohorts, which would extend the timeline to completion. 
Alternatively, new biocontainment units with sufficient capacity could be built. 
 
Taken together, virus manufacturing and dose-finding studies would take at least five months, 
and likely longer. We estimate that, at maximum speed, manufacturing, validation and FDA 
approval of the challenge virus would take four months, and dose-finding four months, for a total 
of eight months. Given these timelines, it is unlikely that HCTs will support testing of the vaccine 
candidates currently in phase 1 or beyond. However, if approached with due urgency, they could 
help accelerate the development of vaccine candidates in earlier developmental stages. The path 
to an HCT will involve dozens of players, and active coordination will be necessary to minimize 
lags arising from interdependencies among them. 
Ethical considerations 
HCTs come with appreciable risks to study participants, research staff, and wider society. It will 
be important for volunteers, manufacturers, regulators, and other stakeholders to assess whether 
those outweigh the potential benefit. 
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The risk to participants has been discussed extensively in other pieces.36 It should be minimized 
by selecting volunteers with low risk of severe disease outcomes, providing state-of-the-art 
medical care, carefully selecting the virus strain and mode of administration, and carefully 
deciding whether a placebo group should be included.37 HCTs must implement an informed 
consent process that ensures participants understand they will be intentionally exposed to an 
infectious pathogen, and that this could cause them to get ill and suffer disease symptoms, 
including uncertain long-term effects.38 Participants must understand that, once exposed to the 
virus, they will only be allowed to leave the study facility when they no longer pose a risk to others, 
even if they decide to withdraw from the data collection aspect of the trial. Further, bioethicists 
and researchers should carefully weigh the virtues of compensation (e.g., paying respect to 
volunteers, enabling their participation) against its potential undesirable effects (e.g., undue 
inducement).38 
 
HCTs also involve potential negative consequences that are less direct. HCTs could 
unintentionally expose trial personnel to the virus, or accidentally release virus into the 
surrounding area, both of which could lead to wider outbreaks. Teams leading HCTs should 
consult the local community and other relevant stakeholders well beforehand and take all 
necessary measures to minimize these risks.36 
 
Finally, in rushing to conduct HCTs to evaluate COVID-19 vaccine candidates, the biomedical 
community may risk deleterious outcomes that could set back the field of human challenge 
research significantly. Recent research using human challenges has yielded valuable insights for 
the control of influenza, typhoid and other infectious diseases, and an overly hasty or mismanaged 
COVID-19 HCT could risk the gains from future HCTs.39, 40 
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Conclusion 
We presented three potential use cases for HCTs in accelerating COVID-19 vaccine 
development: evaluating efficacy, converging on CoPs, and improving understanding of 
pathogenesis and the human immune response. In each of these, HCTs offer distinct advantages 
due to the speed and richness of the data they could generate. However, practical and ethical 
considerations constrain the range of scenarios in which HCTs could actually influence vaccine 
development timelines. For example, even if HCTs were pursued immediately, it is unlikely they 
could provide efficacy data on the current phase 1 vaccine candidates soon enough to be useful. 
 
Nevertheless, there are still many scenarios in which the benefits generated by HCTs would likely 
outweigh their risks. For example, it is quite possible that we will reach the end of 2020 without 
any of the vaccine candidates currently in clinical trials having shown efficacy, but with one or 
more drugs having proven effective against severe COVID-19, and a range of vaccine candidates 
in early developmental stages. In such circumstances, it could make sense to run a large, multi-
arm HCT of, say, a dozen vaccine candidates in parallel with a multi-arm phase 3 trial. This could 
provide both rapid efficacy data to be used in down-selecting candidates and rapid confirmation 
of any CoPs indicated in phase 2 trials. 
 
To preserve the option to implement HCTs in such scenarios, we recommend an immediate, 
coordinated effort by all stakeholders to make the necessary preparations. These include: 
 
1. Convening experts to discuss the ethical and practical considerations associated with 
HCTs for COVID-19, concluding in a set of recommendations and guidelines for their use 
in the present pandemic and their role in the licensure process. The WHO and the NIH 
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have already started this process. (Notably, this could provide useful guidance in the event 
of future pandemics as well.) 
2. Taking the first practical steps toward HCTs, including preparing challenge virus and 
making preliminary arrangements with volunteers, vaccine developers, regulators, 
academic institutions, and clinical researchers to run HCTs in situations where they are 
expected to be highly useful, 
3. periodically conducting a systematic re-evaluation, and adjusting course based on the 
progress of the pandemic and the first drug and vaccine trials. 
 
HCTs have the potential to considerably shorten the COVID-19 pandemic, saving many lives and 
enabling economies and societies to return to normality. But we must act now to ensure this 
opportunity is not missed. 
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